Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ResMed's Ending Cash Position for the quarter that ended in Mar. 2026 was MXN29,944 Mil.
ResMed's quarterly Ending Cash Position
increased
from Sep. 2025 (MXN25,386 Mil) to Dec. 2025 (MXN25,515 Mil) and
increased
from Dec. 2025 (MXN25,515 Mil) to Mar. 2026 (MXN29,944 Mil).
ResMed's annual Ending Cash Position
increased
from Jun. 2023 (MXN3,907 Mil) to Jun. 2024 (MXN4,367 Mil) and
increased
from Jun. 2024 (MXN4,367 Mil) to Jun. 2025 (MXN22,773 Mil).
ResMed Ending Cash Position Related Terms
ResMed Ending Cash Position Historical Data
* Premium members only.
The historical data trend for ResMed's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
ResMed's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as
What does a Ending Cash Position of MXN29,944 Mil mean?
ResMed (MEX:RMD) has a Ending Cash Position of MXN29,944 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ResMed and its competitors.
Is ResMed's Ending Cash Position too high?
ResMed's current Ending Cash Position is MXN29,944 Mil. Overall, ResMed has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Ending Cash Position compare to MDLN and WST?
ResMed's Ending Cash Position of MXN29,944 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ResMed and its competitors. ResMed's current Ending Cash Position is MXN29,944 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN4,321.08, compared to a current price of MXN3,375.00 — trading 21.9% below its estimated fair value. The current Ending Cash Position is MXN29,944 Mil. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Ending Cash Position is MXN29,944 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,375.00 is trading 21.9% below its estimated GF Value™ of MXN4,321.08.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for MEX:RMD:
Ending Cash Position: MXN29,944 Mil
GF Value™: MXN4,321.08 vs. price of MXN3,375.00 (21.9% below fair value)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
